Keros Therapeutics Files 8-K

TL;DR

Keros filed a routine 8-K, no major news.

AI Summary

Keros Therapeutics, Inc. filed an 8-K on June 3, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.

Why It Matters

This filing indicates Keros Therapeutics is meeting its regulatory reporting obligations with the SEC, which is standard practice for publicly traded companies.

Risk Assessment

Risk Level: low — The filing is a standard regulatory disclosure and does not contain any new material information that would impact risk.

Key Players & Entities

• Keros Therapeutics, Inc. (company) — Registrant
• 0001664710-24-000047 (filing_id) — Accession Number
• June 3, 2024 (date) — Filing Date
• Lexington, Massachusetts (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.0001 — ge on which registered Common Stock, $0.0001 par value per share KROS The Nasdaq Sto

Filing Documents

• kros-20240603.htm (8-K) — 37KB
• exhibit9916324pr.htm (EX-99.1) — 5KB
• 0001664710-24-000047.txt ( ) — 168KB
• kros-20240603.xsd (EX-101.SCH) — 2KB
• kros-20240603_lab.xml (EX-101.LAB) — 22KB
• kros-20240603_pre.xml (EX-101.PRE) — 13KB
• kros-20240603_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On June 3, 2024, Keros Therapeutics, Inc. (the "Company") issued a press release announcing that Jasbir Seehra, the Company's President and Chief Executive Officer, will participate in a fireside chat presentation at the Goldman Sachs 45th Annual Healthcare Conference on Monday, June 10, 2024 at 2:40 p.m. Eastern time. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release dated June 3 , 2024. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KEROS THERAPEUTICS, INC. By: /s/ Jasbir Seehra Jasbir Seehra, Ph.D. Chief Executive Officer Dated: June 3, 2024

View Full Filing

View this 8-K filing on SEC EDGAR